Shanrong Biotechnology Corp
Shanrong Biotechnology Corp. does not have significant operations. Previously, it was operated as a project management and executive consulting company. The company was formerly known as Defense Solutions Holding, Inc. and changed its name to Shanrong Biotechnology Corp. in September 2017. Shanrong Biotechnology Corp. is based in Torrance, California.
Shanrong Biotechnology Corp (SRBT) - Total Assets
Latest total assets as of June 2024: $1.60K USD
Based on the latest financial reports, Shanrong Biotechnology Corp (SRBT) holds total assets worth $1.60K USD as of June 2024.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Shanrong Biotechnology Corp - Total Assets Trend (2008–2023)
This chart illustrates how Shanrong Biotechnology Corp’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Shanrong Biotechnology Corp - Asset Composition Analysis
Current Asset Composition (December 2023)
Shanrong Biotechnology Corp's total assets of $1.60K consist of 100.0% current assets and 0.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 100.0% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2008–2023)
This chart illustrates how Shanrong Biotechnology Corp's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Shanrong Biotechnology Corp's current assets represent 100.0% of total assets in 2023, an increase from 75.7% in 2008.
- Cash Position: Cash and equivalents constituted 100.0% of total assets in 2023, up from 15.2% in 2008.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2008.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Shanrong Biotechnology Corp Competitors by Total Assets
Key competitors of Shanrong Biotechnology Corp based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
464680
KQ:464680
|
Korea | ₩31.23 Billion |
|
Cartesian Growth Corporation III Unit
NASDAQ:CGCTU
|
USA | $281.56 Million |
|
Azure Holding Group Corp
PINK:AZRH
|
USA | $16.92 Million |
|
Constellation Capital Corp.
V:CNST-P
|
Canada | CA$627.53K |
|
Little Fish Acquisition I Corp.
V:LILL-P
|
Canada | CA$56.48K |
|
Hana 30 Special Purpose Acquisition Company
KQ:469880
|
Korea | ₩17.89 Billion |
|
Chicane Capital I Corp.
V:CCIC-P
|
Canada | CA$199.07K |
|
Cuspis Capital II Ltd
V:CCII-P
|
Canada | CA$1.51 Million |
Shanrong Biotechnology Corp - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Shanrong Biotechnology Corp generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Shanrong Biotechnology Corp is currently not profitable relative to its asset base.
Shanrong Biotechnology Corp - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.04 | 0.99 | 2.56 |
| Quick Ratio | 0.04 | 0.99 | 2.56 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-41.25K | $ -12.00 | $ 15.97K |
Shanrong Biotechnology Corp - Advanced Valuation Insights
This section examines the relationship between Shanrong Biotechnology Corp's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 49.92 |
| Asset Growth Rate (YoY) | -89.6% |
| Total Assets | $1.90K |
| Market Capitalization | $94.61K USD |
Valuation Analysis
Premium Asset Valuation: The market values Shanrong Biotechnology Corp's assets at a significant premium ( 49.92x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Shanrong Biotechnology Corp's assets decreased by 89.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Shanrong Biotechnology Corp (2008–2023)
The table below shows the annual total assets of Shanrong Biotechnology Corp from 2008 to 2023.
| Year | Total Assets | Change |
|---|---|---|
| 2023-12-31 | $1.90K | -89.64% |
| 2022-12-31 | $18.30K | -26.16% |
| 2017-12-31 | $24.78K | -87.00% |
| 2009-12-31 | $190.55K | -52.91% |
| 2008-12-31 | $404.68K | -- |